Does Aurora’s (TSX:ACB) Latest Update Make the Stock a Buy Heading Into Earnings?

Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) provided investors with an update related to its upcoming Q4 results, but will it be enough to help rally the stock?

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB) is expected to release its year-end results around mid-September. However, last week, the company gave investors an update with respect to how it has been doing and where it expects to finish the year.

In the past, the company issued warnings stating that it was going to miss expectations. However, this time around, things were a lot more positive, as the company said that it expected to do better than expected.

Previously, the company stated that its production would be around 25,000 kilograms for the quarter, and now, it expects that amount to be closer to 30,000 kilograms.

Net revenue for Q4 is also expected to reach between $100 million to $107 million, which would be an astronomical increase from the $19.1 million that it generated in sales just one year ago.

For the full year, Aurora expects revenue after excise to reach between $249 million to $256 million. For fiscal 2018, Aurora’s sales were $55 million.

In addition to sales, Aurora noted that it anticipates improvements in many key performance indicators, including gross margin and cash costs per gram produced.

While the company did mention that it “continues to track toward positive adjusted EBITDA,” it didn’t provide any figures on where it expects its bottom line to come in at.

Key takeaways for investors

What stood out to me was what Aurora didn’t talk about in its update. There was no mention of profits, earnings or cash flow in its press release. Given where the industry is today, these are some of the most important numbers for investors.

As strong as the company’s sales growth is, if Aurora is still nowhere near profitability or generating positive cash flow, then it still might not be enough to get investors on board.

If the best the company can do is to say that it is “on track” to reach a positive adjusted EBITDA number, that tells me it has a long way to go to becoming profitable.

EBITDA excludes non-cash items while adjusted EBITDA takes out even more expenses out of the mix. While some people may argue that non-recurring or irregular expenses shouldn’t be included in the earnings number, the reality is for a company that’s growing as rapidly as Aurora is, a case can be made that they’re part of the company’s foreseeable future and that they shouldn’t be brushed aside.

As long as expansion and acquisition are part of the company’s strategy, costs related to that should be considered as well.

Aurora has struggled heavily over the past few months and it’s going to need a strong finish to the year if it wants to get its stock price back up.

Bottom line

While Aurora expects to see an improvement in its top line for Q4, I’m not optimistic that we’ll see much improvement further down the company’s financials. Until that happens, Aurora is still going to be a risky investment.

Cannabis investors have been looking for more than just revenue growth from a company, and if Aurora posts a big loss in its year-end results, its strong sales numbers may do little to prevent the stock from plummeting further down in price.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »